Teligent, Inc. (NASDAQ:TLGT) was downgraded by investment analysts at TheStreet from a “c-” rating to a “d+” rating in a research note issued on Wednesday.

Several other brokerages also recently issued reports on TLGT. Zacks Investment Research downgraded Teligent from a “hold” rating to a “sell” rating in a research report on Thursday, July 6th. Deutsche Bank AG restated a “hold” rating and issued a $9.00 price objective (up from $8.00) on shares of Teligent in a research report on Monday, July 17th. ValuEngine downgraded Teligent from a “hold” rating to a “sell” rating in a research report on Tuesday, July 25th. BidaskClub downgraded Teligent from a “hold” rating to a “sell” rating in a research report on Monday, July 24th. Finally, Canaccord Genuity began coverage on Teligent in a research report on Monday, July 31st. They issued a “buy” rating and a $11.00 price objective on the stock. Two analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $9.33.

Teligent (NASDAQ:TLGT) last issued its quarterly earnings data on Tuesday, August 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.02 by ($0.04). Teligent had a negative net margin of 11.36% and a positive return on equity of 1.49%. The company had revenue of $18.40 million during the quarter, compared to analysts’ expectations of $20.11 million. During the same quarter in the prior year, the company earned $0.02 earnings per share. The firm’s revenue was up 7.4% compared to the same quarter last year.

WARNING: This report was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/11/03/teligent-inc-tlgt-downgraded-by-thestreet-to-d.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers lifted its position in Teligent by 0.4% during the second quarter. Rhumbline Advisers now owns 49,622 shares of the company’s stock worth $454,000 after buying an additional 200 shares during the period. Teachers Advisors LLC lifted its position in Teligent by 1.0% during the fourth quarter. Teachers Advisors LLC now owns 65,454 shares of the company’s stock worth $433,000 after buying an additional 648 shares during the period. Wells Fargo & Company MN lifted its position in Teligent by 3.1% during the first quarter. Wells Fargo & Company MN now owns 45,617 shares of the company’s stock worth $357,000 after buying an additional 1,369 shares during the period. American International Group Inc. lifted its position in Teligent by 7.1% during the first quarter. American International Group Inc. now owns 25,488 shares of the company’s stock worth $199,000 after buying an additional 1,680 shares during the period. Finally, Creative Planning lifted its position in Teligent by 17.4% during the third quarter. Creative Planning now owns 13,500 shares of the company’s stock worth $103,000 after buying an additional 2,000 shares during the period. Hedge funds and other institutional investors own 66.56% of the company’s stock.

Teligent Company Profile

Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.

Receive News & Ratings for Teligent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.